Secondary prevention of colorectal cancer

Tereza Dušičková, Sylva Bártlová
University of South Bohemia in České Budějovice, Faculty of Health and Social Sciences, Institute of Nursing, Midwifery and Emergency Care, České Budějovice,Czech Republic

Korespondenční autor: Tereza Dušičková (dusict00@jcu.cz)

ISSN 1804-7181 (On-line)

Full verze:

Submitted:23. 5. 2019
Accepted: 6. 6. 2019
Published online: 31. 12. 2019

Summary

Goal: The goal of this review study is to map the options of secondary prevention of colorectal cancer.

Methods: We used the method of document content analysis. We searched for references using the following keywords: “screening”, “colorectal cancer”, “occult bleeding”, “colonoscopy”, and the Boole operators “AND” and “NOT”. We used the databases of EBSCO, ProQuest and Pubmed between February and April 2019. After the filtering, we included 20 sources.

Results: The study shows that if colorectal cancer is treated in the early phase, there is a higher probability of survival. We also confirmed a decreased incidence and mortality using the screening of risk groups. The colorectal carcinoma screening is carried out by testing the stool or colonoscopy. To test the stool, we can use haemoccult (gFOBT), immunochemical techniques (FIT) or DNA mutation testing in the stool.

Conclusions: There is not a unanimous recommendation for colorectal carcinoma screening. Some countries have state regulations. This research shows that there is not sufficient proof for using haemoccult tests or immunochemical techniques.

Keywords: Colorectal tumour; Diagnostics; Nurse; Screening; Secondary prevention

Literatura

1. Adam Z, Vorlíček J, Vaníček J, et al. (2004). Diagnostické a léčebné postupy u maligních chorob [Diagnostic and therapeutic procedures for malignant diseases]. Praha: Grada (Czech).
2. Birkenfeld S, Belfer RG, Chared M, Vilkin A, Barchana M, Lifshitz I, et al. (2011). Factorsaffectin­gcompliance in faecaloccultblo­odtesting: a cluster randomized study ofthefaecalim­munochemical test versus theguaiacfaeca­loccult test. J Med Screen 18(3): 135–141. DOI: 10.1258/jms.2011­.010147.
3. Bortlík M (2005). Kolorektální karcinom [Colorectal tumour]. In: Lukáš K et al. (Eds). Gastroenterologie a hepatologie pro zdravotní sestry [Gastroenterology and hepatology for nurses]. Praha: Grada, pp. 195–202 (Czech).
4. Brenner H, Tao S (2009). Superior diagnostic performance offacealimmunoche­micaltestsfor­haemoglobinina­head to headcomparison­withguiacbased­faecaloccultblo­odtestsamong 2235 participan­tsofscreeningco­lonoscopy. Eur J Cancer 49(14): 3049–3054. DOI: 10.1016/j.ejca­.2013.04.023.
5. Bretthauer M, Kaminski MF, Løberg M, Zauber AG, Regula J, Kuipers EJ, et al. (2016). Population-BasedColonosco­pyScreeningfor­ColorectalCan­cer: A RandomizedCli­nical Trial. JAMA Inter Med 176(7): 894–902. DOI: 10.1001/jamain­ternmed.2016.0960.
6. Chiu HM, Chiu HM, Chang LC, Hsu WF, Chou CK, Wu MS (2015). Non-invasivescree­ningforcolorec­talcancer in Asia. Best PractClinGastro­enterol 29(6): 953–965. DOI: 10.1016/j.bpg­.2015.09.015.
7. Chrastina J (2009). Principy testů určených k detekci okultního krvácení do stolice a jejich charakteristika [Principles of tests to detect faecal occult blood and their characteristics]. Interní med 11(4): 193–196 (Czech).
8. Deutekom M (2010). Comparisonofguaiac and immunological­fecaloccultblo­odtests in colorectalcan­cerscreening: thepatientper­spective. Scand J Gastroenterol 45(11): 1345–1349. DOI: 10.3109/003655­21.2010.497937.
9. Epidemiologie zhoubných nádorů v České republice [Epidemiology of malignant tumours in the Czech Republic] (2018). [online] [cit. 2019–04–22]. Availablefrom: http://www.svod.cz/ (Czech).
10. Falt P, Urban O, Suchánek Š, Cyrany J, Bortlík M, Martínek J, et al. (2016). Doporučené postupy České gastroenterologické společnosti ČLS JEP pro diagnostickou a terapeutickou koloskopii [Recommended procedures of the Czech Gastroenterology Society of ČLS JEP for diagnostic and therapeutic coloscopy]. Gastroenterologie a hepatologie 70(6): 523–538. DOI: 10.14735Ȁamgh2016csgh­.info (Czech).
11. Fraňková S, Synytsya A (2017). Metody diagnózy nádorových onemocnění plic a tlustého střeva [Methods of diagnosis of lung and colon cancer]. Chemické listy 111(8): 502–508 (Czech).
12. Hoffman RM, Steel S, Yee EF, Massie L, Schrader RM, Murata GH (2010). Colorectalcan­cerscreening adherence ishigherwithfe­calimmunochemi­calteststhangu­aiac-basedfecaloccul­tbloodtests: a randomized, controlled trial. Prev Med 50(5–6): 297–299. DOI: 10.1016/j.ypmed­.2010.03.010.
13. Hol L, van Leerdam ME, van Ballegooijen M, van Vuuren AJ, van Dekken H, Reijerink JC (2010). Screeningforco­lorectalcancer: randomised trial comparingguaiac-based and immunochemical­faecaloccultblo­odtesting and flexiblesigmo­idoscopy. Gut 59(1): 62–68. DOI: 10.1136/gut.2009­.177089.
14. Holubec L, et al. (2004). Kolorektální karcinom: současné možnosti diagnostiky a léčby [Colorectal carcinoma: current options in diagnosis and treatment]. Praha: Grada (Czech).
15. Imperiale TF, Ranshoff DF, Itkowitz SH, Levin TR, Lavin P, Lidgard GP, et al. (2014). Multitargetstool DNA testingforcolo­rectal-cancerscreening. N Engl. J Med 370: 1287–1297. DOI: 10.1056/NEJMo­a1311194.
16. Janíková E, Zeleníková R (2013). Ošetřovatelská péče v chirurgii [Nursing care in surgery]. Praha: Grada (Czech).
17. Pioche M, Ganne C, Gincul R, De Leusse A, Marsot J, Balique J, et al. (2018). Coloncapsule versus computedtomograp­hycolonography­forcolorectal­cancerscreening in patientswith positive fecaloccultblood test whorefusecolo­noscopy: a randomized trial. Endoscopy 50(8): 761–769. DOI: 10.1055/s-0044–100721.
18. Quintero E, Carrillo M, Gimeno-García AZ, Hernández-Guerra M, Nicolás-Pérez D, Alonso-Abreu I, et al. (2014). Equivalencyof­fecalimmunoche­micaltests and colonoscopy in familialcolorec­talcancerscre­ening. Gastroenterology 147(5): 1021–1030. DOI: 10.1053/j.gas­tro.2014.08.004.
19. Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á, et al. (2012). Colonoscopy versus fecalimmunoche­micaltesting in colorectal-cancerscreening. N Engl J Med 366(8): 697–706. DOI: 10.1056/NEJMo­a1108895.
20. Roslani AC, Abdullah T, Arumugam K (2012). Screeningforco­lorectalneopla­siaswithfecaloc­cultbloodtests: false-positive impactof non-dietaryrestriction. Asian Pac J CancerPrev 13(1): 237–241. DOI: 10.7314/apjcp­.2012.13.1.237.
21. Šachlová M, Májek O (2015). Screening kolorektálního karcinomu [Colorectal cancer screening]. Onkologie 9(4): 162–166 (Czech).
22. Schneiderová M (2014). Perioperační péče [Perioperative care]. Praha: Grada (Czech).
23. Segnan N, Patnick J, von Karsa L (2010). Europeanguide­linesforquali­tyassurance in colorectalcan­cerscreening and diagnosis. Luxembourg: Publications Office oftheEuropean U­nion.
24. Seifert B, Májek O, Zavoral M, Král N, Suchánek S, Ngo O, Dušek L (2014). Resultsofthe Czech NationalColorec­talCancerScre­eningProgramme – FaecalOccultBlo­odTests. Klin Onkol 27(Suppl. 2): 87–97 (Czech).
25. Shapiro JA, Bobo JK, Church TR, Rex DK, Chovnick G, Thompson TD, et al. (2017). A comparisonof­fecalimmunoche­mical and high-sensitivity guaiactestsfor­colorectalcan­cerscreening. Am J Gastroenterol 112(11): 1728–1735. DOI: 10.1038/ajg.2017­.285.
26. Skála B (2018). Prevence a screening onkologických onemocnění [Cancer prevention and screening]. Praha: Společnost všeobecného lékařství ČLS JEP (Czech).
27. Spáčilová Z, Solgajová A, Vörösová G, Zrubcová D (2018). Exogenous risk factorsforcolo­rectalcancer in peopleaged 50 years and older. Kontakt 20(2): 126–133. DOI: 10.1016/j.kon­takt.2017.11.005.
28. Suchánek Š, et al. (2017). Screening kolorektálního karcinomu [Colorectal cancer screening]. In: Špičák J et al. (Eds). Novinky v gastroenterologii a hepatologii II [News in gastroenterology and hepatology]. Praha: Grada, pp. 15–21 (Czech).
29. Suchánek Š, Vepřeková G, Májek O, Dušek L, Zavoral M (2011). Epidemiologie, etiologie, screening a diagnostika kolorektálního karcinomu, včetně diagnosticko-terapeutických zákroků na tlustém střevě [Epidemiology, etiology, screening and diagnosis of colorectal cancer, including diagnostic-therapeutic interventions in the colon]. Onkologie 5(5): 261–265 (Czech).
30. Symonds EL, Pedersen S, Cole SR, Massolino J, Byrne D, Guy J, et al. (2015). Improvingparti­cipation in colorectalcan­cerscreening: a randomisedcon­trolled trial ofsequentialof­fersoffaecalthen­bloodbased non-invasivetests. Asian Pac J CancerPrev 16(18): 8455–8460. DOI: 10.7314/apjcp­.2015.16.18.8455.
31. US PreventiveSer­vicesTaskForce, Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, et al. (2016). ScreeningforCo­lorectalCancer US PreventiveSer­vicesTaskForce­Recommendation­Statement. JAMA 315(23): 2564–2575. DOI: 10.1001/jama.2016­.5989.
32. Vyhláška č. 317/2016 Sb., kterou se mění vyhláška č. 70/2012 Sb., o preventivních prohlídkách [Regulation No. 317/2016 Coll., which ammends the regulation No. 70/2012 Coll. on preventative check-ups]. In: Sbírka zákonů České republiky, částka 124/2016, p. 4837 (Czech).
33. Wang H, Wang P, Liu X, Li L, Xiao X, Liu P, et al. (2019). Factorspredic­tingthecolorec­taladenomadetec­tionrate in colonoscopicscre­eningof a Chinesepopulation: A prospective study. Medicine (Baltimore) 98(15): e15103. DOI: 10.1097/MD.00000000000­15103.
34. Zavoral M, Grega T, Suchánek Š (2016). Komplikace léčby kolorektálního [Complications in the treatment of colorectal cancer]. Onkologie 10(1): 41–47 (Czech).
35. Zikán M, Cibula D (2009). Prevence a screening zhoubných nádorů [Prevention and screening of malignant tumours]. In: Cibula D, Petruželka L, et al. (Eds). Onkogynekologie. Praha: Grada, pp. 93–96 (Czech).
36. Zorzi M, Fedeli U, Schievano E, Bovo E, Guzzinati S, Baracco S, et al. (2015). Impact on colorectalcancer mortality ofscreeningpro­grammesbased on thefaecalimmu­nochemical test. Gut 64(5): 674–690. DOI: 10.1136/gutjnl-2014–307508.